ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Tango Therapeutics Inc

Tango Therapeutics Inc (TNGX)

3.71
-0.37
( -9.07% )
Updated: 05:38:38

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
3.71
Bid
3.71
Offer
3.72
Volume
2,022,205
3.58 Day's Range 4.22
2.70 52 Week Range 13.005
Market Cap
Previous Close
4.08
Open
4.07
Last Trade
1
@
3.715
Last Trade Time
05:38:56
Financial Volume
US$ 7,954,622
VWAP
3.9336
Average Volume (3m)
1,898,956
Shares Outstanding
107,417,818
Dividend Yield
-
PE Ratio
-3.85
Earnings Per Share (EPS)
-0.95
Revenue
36.53M
Net Profit
-101.74M

About Tango Therapeutics Inc

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Tango Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker TNGX. The last closing price for Tango Therapeutics was US$4.08. Over the last year, Tango Therapeutics shares have traded in a share price range of US$ 2.70 to US$ 13.005.

Tango Therapeutics currently has 107,417,818 shares in issue. The market capitalisation of Tango Therapeutics is US$438.26 million. Tango Therapeutics has a price to earnings ratio (PE ratio) of -3.85.

TNGX Latest News

Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

– Positive TNG462 clinical activity across multiple tumor types in the phase 1/2 clinical trial, program moving into full development with multiple combination studies – – Clinical collaboration...

Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program

– TNG462 demonstrated durable clinical activity across multiple tumor types, including non-small cell lung cancer (NSCLC) and pancreatic cancer, in ongoing phase 1/2 clinical trial, moving into...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.061.643835616443.654.223.530942283.88518512CS
4-2.47-39.96763754056.186.982.734210023.82922998CS
12-7.69-67.456140350911.411.922.718989565.57672376CS
26-3.92-51.3761467897.6312.0152.712715336.66445178CS
52-3.88-51.11989459827.5913.0052.79460837.57983127CS
156-8.2-68.849706129311.9113.032.476745727.40406089CS
260-5.9-61.39438085339.6118.842.476346227.60985813CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WORXSCWorx Corporation
US$ 2.04
(108.16%)
126.87M
CRNCCerence Inc
US$ 5.7206
(102.86%)
54.7M
SPAISafe Pro Group Inc
US$ 4.57
(42.81%)
38.81M
PROCProcaps Group SA
US$ 0.7792
(36.34%)
952.41k
ARQQArqit Quantum Inc
US$ 10.00
(36.24%)
502.01k
SKKSKK Holdings Limited
US$ 1.43
(-68.64%)
16.63M
TMTCTMT Acquisition Corporation
US$ 2.27
(-64.75%)
171.1k
WCTWellchange Holdings Company Limited
US$ 1.31
(-60.54%)
1.4M
GLXGGalaxy Payroll Group Ltd
US$ 2.06
(-47.31%)
2.02M
PYXSPyxis Oncology Inc
US$ 2.125
(-44.37%)
12.28M
CDTConduit Pharmaceuticals Inc
US$ 0.1126
(21.99%)
540.05M
NVDANVIDIA Corporation
US$ 146.0552
(0.11%)
267.83M
ELABElevai Labs Inc
US$ 0.0206
(-3.74%)
197.59M
AKTSAkoustis Technologies Inc
US$ 0.1037
(19.06%)
195.11M
WORXSCWorx Corporation
US$ 2.04
(108.16%)
126.87M

Your Recent History

Delayed Upgrade Clock